Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.

Slides:



Advertisements
Similar presentations
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors Ji-Man Kang, Yae-Jean Kim,
Advertisements

Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically.
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation  Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.
Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation.
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.
How to Treat MDS without Stem Cell Transplantation
Unrelated Donor Bone Marrow Transplants for Severe Aplastic Anemia with Conditioning Using Total Body Irradiation and Cyclophosphamide  Sung-Yong Kim,
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.
Increased Copy Number of the Interleukin-6 Receptor Gene Is Associated with Adverse Survival in Multiple Myeloma Patients Treated with Autologous Stem.
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.
Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis  Danielle H. Oh, Haocheng.
Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia  Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.
Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.
Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome 
Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study 
Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia  Paul M. Armistead, Marcos.
Sabina Kersting, Leo F. Verdonck 
Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.
Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors  Ji-Man Kang, Yae-Jean Kim,
Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome  Sung-Soo Park, Young-Woo.
High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Stratification of de novo Adult Acute Myelogenous Leukemia with Adverse-Risk Karyotype: Can We Overcome the Worse Prognosis of Adverse-Risk Group Acute.
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.
Cytomegalovirus Reactivation Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Chemotherapeutics.
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in.
Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple.
Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous Stem Cell Transplantation 
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma  Christopher Parrish, Amin Rahemtulla, Jim.
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
Polymorphisms in Genes That Regulate Cyclosporine Metabolism Affect Cyclosporine Blood Levels and Clinical Outcomes in Patients Who Receive Allogeneic.
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma  Dharshan Sivaraj, Michael.
Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma 
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant  Ahmad Hatem Mattour,
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival  Victor H. Jimenez-Zepeda,
What is quality in a transplant program?
Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation 
Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.
Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives  Minakshi Raj, Sung Won Choi,
Blood and Marrow Transplant Handbook
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia  SungNam Lim, Je-Hwan Lee, MD, PhD,
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Luciano J. Costa, Jia-Xing Huang, Parameswaran.
Graft-versus-Tumor Effect According to Type of Graft-versus-Host Disease Defined by National Institutes of Health Consensus Criteria and Associated Outcomes 
Presentation transcript:

Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation  Jin Seok Kim, Kihyun Kim, June-Won Cheong, Yoo Hong Min, Cheolwon Suh, Hawk Kim, Deog Yeon Jo, Hun Mo Ryoo, Sung Soo Yoon, Jae Hoon Lee  Biology of Blood and Marrow Transplantation  Volume 15, Issue 4, Pages 463-470 (April 2009) DOI: 10.1016/j.bbmt.2008.12.512 Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 OS curves of 197 MM patients after ASCT (Kaplan-Meier curves). (A) OS after ASCT according to the response status before ASCT. (B) OS according to the response status before ASCT in the MM patients who received VAD induction chemotherapy (n = 162). (C) OS according to the response status after ASCT. (D) OS according to the continuity of CR after ASCT in the MM patients who achieved CR after ASCT (n = 147). Biology of Blood and Marrow Transplantation 2009 15, 463-470DOI: (10.1016/j.bbmt.2008.12.512) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.